SYNthesis med chem opens UK lab

Melbourne-headquartered CRO SYNthesis med chem has expanded, opening a new facility in the UK.

The company says it new facility at the Babraham Research Campus in Cambridge will allow it to add UK-based medicinal chemistry expertise to its portfolio.

It will also allow SYNthesis to provide European customers with local project-management capabilities for their synthetic and medicinal chemistry projects.

“With an increasing customer base across Europe, it was essential that we put in place the infrastructure and resources to deliver the required levels of support for all our medicinal and synthetic chemistry projects,” SYNthesis co-founder and executive chairman Professor Andrew Wilks said.

“The new Cambridge facility does that, but also gives us the capacity to grow as we attract new customers.”

SYNthesis also operates labs in Melbourne and in Shanghai, China. The company was founded in 2007, based on the business model of combining Western medicinal chemistry expertise with the cost-effective and scalable synthetic chemistry capacity available in China.